Oncology & Hematology Clinical Trial Experience

A deep bench of knowledge that pairs oncology development expertise with wide-ranging rare disease experience in the largest areas of unmet need, including new treatments in cell and gene therapies and immuno-oncology.

prcom_Asset 1ARROW

The tireless pursuit of novel oncology treatments

The new course of cancer therapy

Precision medicine – devising patient-specific treatments to combat diseases once considered incurable – is radically changing the way the world looks at cancer therapy. The leaders in this field are small biotech and specialty pharmaceutical companies – organizations sometimes no larger than a few people and a single molecule. Our clinical trial expertise helps you get from brilliant idea to life-changing reality.

Why choose Premier?
  • More than 170 hematology and oncology clinical trials completed through every phase, including multiple rare cancer and cell and gene therapy studies
  • Expertise ranging from small dose-finding studies to large multinational trials
  • Every aspect, from trial design and investigators to sites and patient selection, customized for your indication – including preferential regulatory pathways and other strategies for successful early planning and engagement


Precision cancer drugs

For the full potential of precision medicine to be realized, regulatory, technical, clinical, and economic frameworks will need to evolve to the nuances of these novel treatments.


Finding the fast track

Sponsors of first-in-human trials of novel oncology compounds face significant challenges. Track a hypothetical drug through its development paces, exploring the many aspects you must consider when performing early-stage oncology research.

Featured Resources



Immuno-Gene Therapeutics in Hematological Cancers: How Science Drives Study Strategy



Six Dosing and Safety Considerations in the Era of Emerging Therapies



Premier Voices #1: Rare Oncology w/ Colin Hayward and Peter Larson

Premier Thought Leadership

Luke Gill

Luke Gill heads our hematology/oncology group and has more than 20 years of drug development experience behind him. Specializing in oncology, he has led numerous global CRO management teams and provided strategic assessment, management, and oversight of study enrollment and program metrics. Luke holds a master’s degree in neuro and molecular pharmacology from the University of Bristol, a bachelor’s degree in biological sciences from the University of the West of England, and an MBA specializing in strategy and international enterprise from the Open University in the U.K.

Connect with us

Ready to get started? So are we. Drop us a line to learn more about how we can help.